1309889-22-2

Upstream product

• 1309888-81-0 C₃₃H₄₅BrN₄O₁₀S₂ 
• 1309889-23-3 C₂₈H₃₇BrN₄O₈S₂*ClH 
• 25016-20-0 1-methylpyrazole-3-carboxylic acid 
• 1309888-80-9 C₂₉H₃₆BrN₃O₈S 
• 1309888-79-6 C₂₉H₃₈BrN₃O₉S 
• 861397-55-9 C₃₀H₄₀BrN₃O₉S 
• 1309888-72-9 C₃₂H₄₄BrN₃O₉S 
• 1098199-68-8 C₁₈H₂₁BrN₂O₆S*ClH 
• 924307-76-6 (S)-2-amino-8-nonenoic acid 
• 801282-60-0 C₂₃H₂₉BrN₂O₈S 
• 300831-21-4 (S)-2-(tert-butoxycarbonylamino)non-8-enoic acid 

Relevant academic research and scientific papers

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of Formula (I) wherein R1, R2, R3, R4 and R5 are defined herein, maintain good activity against NS3 proteases containing clinically relevant genotype 1a R155K and genotype 1b D168V resistance mutations. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of the invention, which are macrocyclic peptide analogs containing an acylsulfonamide moiety, maintain good activity against NS3 proteases containing clinically relevant resistance mutations for this class as represented by genotype 1 a R155K, genotype 1 b D168V and genotype 1 a D168V resistance mutations. The compounds of the invention are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.